Glaukos Corporation (NYSE:GKOS) Q1 2026 Earnings Call Transcript
Operator: Welcome to Glaukos Corporation's First Quarter 2026 Financial Results Conference Call.
Glaukos Corp (GKOS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 1,446,926 | $155,776,053 | +5268% | 0.03% |
| 2. | Holocene Advisors Brandon Haley | 1,383,715 | $148,970,757 | +7% | 0.36% |
| 3. | Millennium Management Israel Englander | 1,173,696 | $126,360,111 | -28% | 0.05% |
| 4. | Braidwell LP Alex Karnal | 763,505 | $82,198,948 | -18% | 2.74% |
| 5. | Driehaus Capital Richard Driehaus | 487,912 | $52,528,606 | 0.39% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $23.84 | 2,100 | $50,064.00 | 102,100 | 2017-11-22 | Filing | |
| $16.03 | 2,500 | $40,075.00 | 5,000 | 2016-03-04 | Filing | |
| $15.30 | 1,388 | $21,236.40 | 1,388 | 2015-12-31 | Filing | |
| $15.30 | 1,388 | $21,236.40 | 4,656 | 2015-12-31 | Filing | |
| $21.83 | 2,500 | $54,575.00 | 2,500 | 2015-11-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $140.76 | 5,000 | $703,800.00 | 35,528 | 2026-05-14 | Filing | |
| $135.00 | 5,000 | $675,000.00 | 35,528 | 2026-05-11 | Filing | |
| $140.00 | 10,000 | $1,400,000.00 | 43,681 | 2026-04-30 | Filing | |
| $143.54 | 19,573 | $2,809,508.42 | 73,419 | 2026-05-01 | Filing | |
| $143.35 | 1,700 | $243,695.00 | 19,739 | 2026-05-01 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,090,029 | $978,632,521 | 0.02% | |
| 2. | 5,348,395 | $575,844,474 | 0.27% | |
| 3. | 3,370,628 | $362,881,812 | 0.29% | |
| 4. | 3,208,363 | $345,412,361 | 0.01% | |
| 5. | 2,508,771 | $270,094,286 | 0% |
News See All
Strong Results with 38.1% Revenue Growth Lifted Glaukos (GKOS) in Q4
Brown Capital Management, an investment management company, released its fourth quarter 2025 investor letter for “The Brown Capital Management Small Company Fund”. A copy of the letter can be downloaded...
Glaukos Corporation (NYSE:GKOS) Q4 2025 Earnings Call Transcript
Operator: Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today.
What Makes Glaukos (GKOS) a Good Investment?
Fred Alger Management, an investment management company, released its “Alger Weatherbie Specialized Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here.
Glaukos Corporation (NYSE:GKOS) Q3 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. My name is Colby, and I'll be your conference operator today.
Glaukos Corporation (GKOS) Eye Treatment Epioxa Poised for Strong Market Uptake, Says Stifel
Glaukos Corporation (NYSE:GKOS) ranks among the best medical device stocks to invest in.
12 Best Medical Device Stocks to Invest In Now
As chronic diseases like diabetes and cancer become more common, medical device technology is becoming increasingly innovative.
Glaukos Corporation (GKOS) Advances Next-Gen Glaucoma and Corneal Therapies, Eyes FDA Approval for Epioxa
Glaukos Corporation (NYSE:GKOS), a leader in ophthalmic pharmaceutical and surgical therapies, continues to expand its presence in glaucoma, corneal disorders, and retinal diseases through innovative “...
13 Most Oversold Healthcare Stocks So Far in 2025
The healthcare innovation landscape in 2025 is navigating a complex mix of challenges and opportunities, marked by contrasting trends in fundraising, investment, and technology adoption.
Glaukos Corporation (NYSE:GKOS) Q2 2025 Earnings Call Transcript
Operator: Welcome to Glaukos Corporation's Second Quarter 2025 Financial Results Conference Call.
Hedge Fund Resource Center